Colorectal cancer (CRC) is characterized by early metastasis, resistance to anti-cancer therapy, and high mortality rate. Despite considerable progress in the development of new treatment options that improved survival benefits in patients with early-stage or advanced CRC, many patients relapse due to the activation of intrinsic or acquired chemoresistance mechanisms. Recently, we reported novel findings about the role of Jagged1 in CRC tumors with Kras signatures. We showed that Jagged1 is a novel proteolytic target of Kras signaling, which induces Jagged1 processing/activation resulting in Jag1-ICD release, which favors tumor development in vivo, through a non-canonical mechanism. Herein, we demonstrate that OXP and 5FU cause a strong accumulation of Jag1-ICD oncogene, through ERK1/2 activation, unveiling a surviving subpopulation with an enforced Jag1-ICD expression, presenting the ability to counteract OXP/5FU-induced apoptosis. Remarkably, we also clarify the clinical ineffectiveness of gamma-secretase inhibitors (GSIs) in metastatic CRC (mCRC) patients. Indeed, we show that GSI compounds trigger Jag1-ICD release, which promotes cellular growth and EMT processes, functioning as tumor-promoting agents in CRC cells overexpressing Jagged1. We finally demonstrate that Jagged1 silencing in OXP- or 5FU-resistant subpopulations is enough to restore the sensitivity to chemotherapy, confirming that drug sensitivity/resistance is Jag1-ICD-dependent, suggesting Jagged1 as a molecular predictive marker for the outcome of chemotherapy.

5FU/Oxaliplatin-induced Jagged1 cleavage counteracts apoptosis induction in colorectal cancer. A novel mechanism of intrinsic drug resistance / Pelullo, Maria; Zema, Sabrina; De Carolis, Mariangela; Cialfi, Samantha; Giuli, Maria Valeria; Palermo, Rocco; Capalbo, Carlo; Giannini, Giuseppe; Screpanti, Isabella; Checquolo, Saula; Bellavia, Diana. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 12:(2022), pp. 1-10. [10.3389/fonc.2022.918763]

5FU/Oxaliplatin-induced Jagged1 cleavage counteracts apoptosis induction in colorectal cancer. A novel mechanism of intrinsic drug resistance

Pelullo, Maria
Co-primo
;
Zema, Sabrina
Co-primo
;
De Carolis, Mariangela;Cialfi, Samantha;Giuli, Maria Valeria;Palermo, Rocco;Capalbo, Carlo;Giannini, Giuseppe;Screpanti, Isabella;Checquolo, Saula
;
Bellavia, Diana
2022

Abstract

Colorectal cancer (CRC) is characterized by early metastasis, resistance to anti-cancer therapy, and high mortality rate. Despite considerable progress in the development of new treatment options that improved survival benefits in patients with early-stage or advanced CRC, many patients relapse due to the activation of intrinsic or acquired chemoresistance mechanisms. Recently, we reported novel findings about the role of Jagged1 in CRC tumors with Kras signatures. We showed that Jagged1 is a novel proteolytic target of Kras signaling, which induces Jagged1 processing/activation resulting in Jag1-ICD release, which favors tumor development in vivo, through a non-canonical mechanism. Herein, we demonstrate that OXP and 5FU cause a strong accumulation of Jag1-ICD oncogene, through ERK1/2 activation, unveiling a surviving subpopulation with an enforced Jag1-ICD expression, presenting the ability to counteract OXP/5FU-induced apoptosis. Remarkably, we also clarify the clinical ineffectiveness of gamma-secretase inhibitors (GSIs) in metastatic CRC (mCRC) patients. Indeed, we show that GSI compounds trigger Jag1-ICD release, which promotes cellular growth and EMT processes, functioning as tumor-promoting agents in CRC cells overexpressing Jagged1. We finally demonstrate that Jagged1 silencing in OXP- or 5FU-resistant subpopulations is enough to restore the sensitivity to chemotherapy, confirming that drug sensitivity/resistance is Jag1-ICD-dependent, suggesting Jagged1 as a molecular predictive marker for the outcome of chemotherapy.
2022
5FU; CRC; GSIs; Jagged1; drug resistance; oxaliplatin
01 Pubblicazione su rivista::01a Articolo in rivista
5FU/Oxaliplatin-induced Jagged1 cleavage counteracts apoptosis induction in colorectal cancer. A novel mechanism of intrinsic drug resistance / Pelullo, Maria; Zema, Sabrina; De Carolis, Mariangela; Cialfi, Samantha; Giuli, Maria Valeria; Palermo, Rocco; Capalbo, Carlo; Giannini, Giuseppe; Screpanti, Isabella; Checquolo, Saula; Bellavia, Diana. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 12:(2022), pp. 1-10. [10.3389/fonc.2022.918763]
File allegati a questo prodotto
File Dimensione Formato  
Pelullo_Oxaliplatin-induced_2022.pdf

accesso aperto

Note: Articolo
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 6.4 MB
Formato Adobe PDF
6.4 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1659734
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 0
social impact